ReviewMedical oncology (Northwood, London, England)2016
Cancer treatment-related cardiac toxicity: prevention, assessment and management.
Review in Medical oncology (Northwood, London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Chemotherapy cardiotoxicity research in cancer patients: a bibliometric and visual analysis (1994-2024).Frontiers in oncology · 2025Pooled it
- Risk Factors for Anthracycline-Induced Cardiotoxicity.Frontiers in cardiovascular medicine · 2021Pooled it
- Long-Term Response and Remission with Pixantrone in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma: Post-Hoc Analysis of the Multicenter, Open-Label, Randomized PIX301 Trial.Clinical drug investigation · 2018Trial
- Cardiovascular risk in cancer patients: initial experience from a cardio-oncology clinic in Mexico.Archivos de cardiologia de Mexico · 2025Article
- Risk factors for early radiation-induced heart damage in patients undergoing pulmonary SBRT.Echo research and practice · 2025Article
- Multivessel Coronary Artery Disease in Cancer Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.Life (Basel, Switzerland) · 2025Review
- Cardiovascular Magnetic Resonance Imaging in the Early Detection of Cardiotoxicity Induced by Cancer Therapies.Diagnostics (Basel, Switzerland) · 2022Review
- Preparation and Evaluation of Animal Models of Cardiotoxicity in Antineoplastic Therapy.Oxidative medicine and cellular longevity · 2022Review
- The role of cardiac magnetic resonance imaging in the detection and monitoring of cardiotoxicity in patients with breast cancer after treatment: a comprehensive review.Heart failure reviews · 2021Review
- Beta-Blockers and Cancer: Where Are We?Pharmaceuticals (Basel, Switzerland) · 2020Review
- Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association.Circulation research · 2019Review
- Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy.JACC. CardioOncology · 2019Article
- Lung cancer as a cardiotoxic state: a review.Medical oncology (Northwood, London, England) · 2017Review
- Cardiac Imaging: Multimodality Advances and Surveillance Strategies in Detection of Cardiotoxicity.Current oncology reports · 2017Review
- Modulation of caveolins, integrins and plasma membrane repair proteins in anthracycline-induced heart failure in rabbits.PloS one · 2017Article
- Apoferritin as an ubiquitous nanocarrier with excellent shelf life.International journal of nanomedicine · 2017Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer therapies, especially anthracyclines and monoclonal antibodies, have been linked with increased rates of cardiotoxicity. The development of some cardiac side effects happens over several months, and changes in ejection fraction can be detected long before permanent damage or disability occurs. Advanced heart failure could be averted with better and earlier detection. Methodologies for early detection of cardiac changes include stress echocardiograms, cardiac velocity measurements, radionuclide imaging, cardiac MRI and several potential biomarkers. Many agents have been described for prophylaxis of cardiac events precipitated by cancer therapy. Prophylactic use of beta-blockers and ACE inhibitors may be considered for use with trastuzumab in breast cancer as tolerated. Recovery of cardiac function is possible early after the injury from a cancer therapy. Late complications for coronary artery disease, hypertension and arrhythmia are underappreciated. Treatments for severe cancer therapy-related cardiac complications follow the existing paradigms for congestive heart failure and coronary artery disease, although outcomes for cancer patients differ from outcomes for non-cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.